Hepatitis C virus (HCV) core protein is a structural viral protein that packages the viral genomic RNA. In addition to this function, HCV core also modulates a number of cellular regulatory functions. In fact, HCV core protein has been found to modulate the expression of the cyclindependent inhibitor p21 WAF1/CIP1 and to promote both apoptosis and cell proliferation through its physical interaction with p53. Here, we studied the ability of HCV core to bind the p53-related p73 protein, its isoforms and its deletion mutants. We found that HCV core coimmunoprecipitated with p73 in HepG2 and SAOS-2 cells. Deletion mutational analysis of p73 indicates that the domain involved in HCV core binding is located between amino-acid residues 321-353. We also demonstrate that p73/core interaction results in the nuclear translocation of HCV core protein either in the presence of the p73 a or p73 b tumor-suppressor proteins. In addition, the interaction with HCV core protein prevents p73 a, but not p73 b dependent cell growth arrest in a p53-dependent manner. Our findings demonstrate that HCV core protein may directly influence the various p73 functions, thus playing a role in HCV pathogenesis.
Introduction
Hepatitis C virus (HCV) is a major responsible agent for development of chronic hepatitis and hepatocellular carcinoma (HCC), out the mechanism of liver injury in chronic HCV infection is poorly understood. Overexpression of HCV proteins (HCV core, NS3, NS5A) exerts different effects on host cells as cell growth, neoplastic transformation and apoptosis, but the molecular mechanisms involved in the cellular homeostasis alterations are still under investigation.
The HCV capsid core protein is one of the HCV proteins postulated to be involved in hepatocarcinogenesis.
Besides its essential role in virus replication, this protein is involved in many cellular functions (De Francesco, 1999; Koike et al., 2002) . HCV core forms homomultimers, binds RNA, binds C-terminal region of HCV NS5B RNA polymerase, associates with the endoplasmic reticulum, colocalizes on lipid droplets with NS5A and has been shown to interact with several cytoplasmic and nuclear proteins, including apolipoprotein II, lymphotoxin-b and TNF-a type 1 receptor, retinoid X receptor alpha (RXR-alpha) and nuclear ribonucleoprotein K (Barba et al., 1997; Mamiya and Worman, 1999; You et al., 1999; Shi et al., 2002; Tsutsumi et al., 2002; Uchida et al., 2002) . HCV core protein has been shown to modulate transcription, to transform rodent fibroblasts, to immortalize primary hepatocytes and to cause a prolonged Erk1/2 response to mitogenic stimuli (Colombo, 1999; Hayashi et al., 1999; Lu et al., 1999; Jin et al., 2000; Ray et al., 2000; Giambartolomei et al., 2001) . More interestingly, liver expression of HCV core in transgenic mice results in early steatosis (Moriya et al., 1997) and late hepatocarcinoma (HCC) development (Moriya et al., 1998) . Despite all these findings, no unifying opinion has been proposed that could account for a defined role of the HCV core protein in hepatocarcinogenesis. Certainly, the HCV core protein not only affects cellular proliferation, but also modulates apoptosis according to the status of viral infection and cell host. HCV core protein influences cell susceptibility and interacts with different proapoptotic pathways, such as the TNFR I pathway, the Fas/FasL pathway and the p53-dependent apoptosis. In particular, the HCV core protein is able to downregulate (Ray et al., 1996) , but also to upregulate (Otsuka et al., 2000) the functions of the tumor-suppressor gene p53. The p53 superfamily consists of three distinct genes (p53, p63 and p73) that are characterized by a remarkable homology and whose products can function as sequence-specific transcriptional activators (Jost et al., 1997; Levrero et al., 1999) . Both p63 and p73 genes encode multiple isoforms that vary in the N-terminus (DN and DTA) and C-terminus (p73 a, b, g, d, e and z and p63 a, b, g) by alternative splicing. It has been demonstrated that both p63 and p73 are able to transactivate endogenous targets of p53, such as promoter of the cyclin-dependent inhibitor p21 WAF1/CIP1 (Jost et al., 1997) , the promoter of the proapoptotic Bax gene and the Mdm2 promoter (Balint et al., 1999) . Recently, several studies have shown that HCV-related HCCs display a higher expression of DN and DTAp73 in HCC tissues than in non-HCC tissues (Tannapfel et al., 1999; Zemel et al., 2002; Stiewe et al., 2002) . Despite the well-established interaction between HCV core protein and p53 (Ray et al., 1996; Otsuka et al., 2000) , the potential link between HCV core protein and p73 gene products has not been investigated until now. Here we report, for the first time, that the HCV core protein itself is able to interact and to modulate the functions of multiple different p73 isoforms, causing opposite biological effects.
Materials and methods
Plasmids pcDNA3-HA-C2wt and pcDNA3-FLAG-C2wt plasmids, encoding genotype 1a wild-type HCV core protein have been already described (Giambartolomei et al., 2001) . The pcDNA3-HA-based expression vectors for the human p73 isoforms (a, b, g, d) and p53 are described elsewhere (De Laurenzi et al., 1998) . The expression vectors for DNp73 and p73 deletion mutants were generated from the pcDNA3-HAp73 a plasmid by standard and polyacrylamide gel electrophoresis (PCR)-based subcloning techniques Vossio et al., 2002) . PCR primers sequences are available upon request.
Cell lines, cell cultures and transient transfections
Human hepatoma cell lines HepG2 and osteosarcoma SAOS-2 cells were obtained from ATCC. Cells were maintained in Dulbecco's modified medium (DMEM) (Life Technology) supplemented with 10% fetal bovine serum (FBS) at 371C and 5% CO 2 . HepG2 cells were transiently transfected using the Lipofectamine-Plus reagent (Invitrogen), according to the manufacturer's protocol, whereas SAOS-2 cells were transfected by the calcium phosphate precipitation method. In all transfections, the total volume of DNA was maintained constant adding empty vector (pcDNA3-HA). The efficiency of transfection, measured counting cells containing green fluorescent protein (GFP), was 60-70%.
Luciferase assay
Cell lines were transfected with the appropriate expression plasmids together with 0.5 mg/35 mm dish of the reporter plasmids containing the firefly luciferase cDNA under the control of p21 WAF1/CIP1 , Bax and Mdm2 promoters , and 0.02 mg of the control Renilla reniformis (seapansy) luciferase reporter. At 24 h after transfection, cells were lysed and extracts were assayed for luciferase activity using the commercially available dual luciferase kit (Promega). Firefly luciferase activity was normalized to the renilla luciferase activity and expressed as relative luciferase activity with respect to the level obtained after cotransfection of the reporter vector with the empty expression vector.
Immunoprecipitation assay
For immunoprecipitation assay, cells were cotransfected with 2.5 mg/ml/100 mm dishes of each plasmid. Cell extracts were prepared after 24 h in RIPA buffer. Cell extract (400 mg/ml) was incubated overnight at 41C with 10 mg/ml of anti-HA rabbit polyclonal antibody (Santa Cruz Biotechnology). AAgarose beads (30 m1) (Pharmacia) were added to samples, rocked for 1 h at 41C and washed three times with RIPA buffer. The immunoprecipitates were subjected to 12.5% SDS-PAGE. HCV core FLAG-tagged protein was revealed using a mouse monoclonal anti-Flag antibody (Sigma) incubated overnight at 41C. Filters were then exposed to the peroxidase-coupled secondary antibodies for 1 h at room temperature and analysed using the ECL kit (Amersham).
Immunqfluorescence
HepG2 cells were seeded onto coverslips at density of 4 Â 10 3 / dish transfected with 40 ng of pcDNA3-FLAG-C2wt, pcDNA3-HA-p73 b or empty vectors 24 h, later. After 24 h, the cells were washed with PBS, fixed with 4% PBSparaformaldehyde for 15 min, at RT and permeabilized with PBS containing 0.2% Triton X-100 and 0.5% BSA. The cells were incubated 1-2 h at 371C with 1:60 anti-HA rabbit polyclonal antibody (Santa Cruz Biotechnology) and/or 1:60 anti-FLAG mouse monoclonal antibody (Sigma). After three washings in PBS, the cells were again incubated for 30 min with a 1:30 dilution of the anti-mouse TRITC-conjugated and anti-rabbit FITC-conjugated secondary antibodies (Sigma).
Colony formation assay
To perform colony formation assay, cells were transfected in 60 mm dishes with 2.5-5.0 mg of the indicated plasmids. After 2 weeks of selection in culture medium supplemented with 20 ml/ ml G418 (GIBCO BRL), colonies were stained with crystal violet and counted as described (De Laurenzi et al., 1998) .
Statistical analysis
Student's t-test was used to compare continuous variables between groups.
Results
HCV core protein modulates p53 ability to activate the p21 WAF1/CIP1 promoter HCV core protein has been described both as a repressor and an activator of p53 target genes (Ray et al., 1996; Otsuka et al., 2000) . To further characterize the impact of HCV core protein expression on p53 tumor-suppressor functions, we performed cotransfection experiments in osteosarcoma SAOS-2 cells (p53
and negative for p73 expression) and hepatoblastoma HepG2 cells (p53 +/+ and positive for p73 expression) with a wide range of HCV core expression pcDNA3-HA-C2wt plasmid (from 0.08 to 1.6 mg/ml) together with a fixed level of pcDNA3-HA-p53 expression plasmid (10 ng) in the presence of the p21-luc reporter plasmid. As shown in Figure 1 , both in SAOS-2 cells (panel a) and HepG2 cells (panel b), low levels of exogenously expressed HCV core result in a potentiation of p53-induced p21 promoter activation. In contrast, in both cell lines high levels of HCV core expression almost completely abolish p53 ability to activate the p21 reporter plasmid. Accordingly, in HepG2 cells low levels of exogenously expressed HCV core are able to recruit endogenous p53 family proteins to activate p21 promoter-dependent transcription. These findings indicate that HCV core protein modulates the p21 promoter activity, both in p53-positive and p53-negative cellular contexts via p53-dependent and -independent pathways.
HCV core protein modulates p73 a and b proteins ability to activate the p21 WAF1/CIP1 promoter
We then investigated whether HCV core protein also modulates the ability of p73 proteins to activate the p21 promoter. To this aim we performed cotransfection experiments with 0.5 mg of the p21-luc reporter and low and high concentrations of pcDNA3-HA-C2wt plasmid (from 0.08 to 1.6 mg), in the presence of fixed amounts of p73 expression plasmid (20 ng). As shown in Figure 2 , both in SAOS-2 cells (panel a) or in HepG2 cells (panel b) exogenously expressed p73 a and b activate p21-dependent transcription. Similar to what we observed for p53, low levels of exogenously expressed HCV core potentiate the ability of p73 a and b to activate the p21 reporter plasmid in both SAOS-2 and HepG2 cells (Figure 2 , panels a and b). Interestingly, high levels of HCV core expression were able to counteract p73 a activation of p21 promoter activity in a p53-positive and p53-negative cellular context. On the contrary, p73 b was not affected by high HCV core expression in SAOS-2 cells, whereas HCV core ability to inhibit, in this context, p73 b transcriptional activity was restored upon coexpression of p53. These findings may be explained at least in part by the observation that p73 b interacts much better than p73 a with p53, in a yeast two-hybrid system (Kaghad et al., 1997; De Laurenzi et al., 1998) . All together these results indicate that HCV core also modulates p73 a and b transcriptional activity on the p21 promoter and that this property is influenced by p53 state in the case of p73 b.
Differential modulation of p53 target genes by the HCV core protein
We next investigated the effects of HCV core protein on p73 a and b ability to modulate the p53/73 proapoptotic and autoregulatory target genes Bax and Mdm2. As shown in Figure 3b , low levels of exogenously expressed HCV core protein potentiate p53, p73 a and b activity on the Mdm2 promoter. Interestingly, in the case of the Bax promoter, HCV core inhibits p53, p73 a and b dependent activity, irrespectively to its levels of expression ( Figure 3a and data not shown). All together these data demonstrate that HCV core protein exerts a dual dose-dependent effect on p53/p73 target genes involved in growth arrest (i.e. p21) and transcriptional autoregulation of p73 (i.e. Mdm2), whereas it always inhibits, independently of cellular conditions, the proapoptotic Bax promoter. These findings open a glimmer of light to understand the controversial indications reported about the role of HCV core protein in regulating cell cycle and cell viability.
HCV core protein physically interacts with the C-terminal region (aa 321-353) of p73 proteins
Our results demonstrate that HCV core modulates p73-dependent transcription, but do not clarify how this functional interaction may occur. Indeed, HCV core protein might interfere with p73 activating signals or might modulate p73 functions by a protein-protein interaction. To investigate this latter possibility, we performed coimmunoprecipitation experiments in HepG2 and SAOS-2 cells. Firstly, 2.5 mg of p53 and 2.5 mg p73 a HA-tagged expression plasmids were cotransfected both in HepG2 and in SAOS-2 cells with 2.5 mg HCV core FLAG-tagged plasmid. Cell extracts were immunoprecipitated with a rabbit polyclonal antibody directed against the HA sequence and revealed with a mouse polyclonal antibody directed against the FLAG fragment. As shown in Figure 4a , both p53 (Lu et al., 1999; Otsuka et al., 2000) and p73 a were coimmunoprecipitated with the HCV core protein in HepG2 cells. Similar results were obtained in SAOS-2 cells (data not shown). This result indicates that the HCV core protein can directly bind p73 a as well as p53 protein. We also tested HCV core protein ability to bind the p73 a, b, g and d isoforms. As shown in Figure 4b , all four different p73 isoforms bind the HCV core protein, with a lower affinity for the C-terminus truncated p73 d isoform. To map the region of the p73 proteins involved in the p73/core interaction, we performed coimmunoprecipitation experiments using HepG2 cells cotransfected with HCV core associated with different p73 deletion mutant expression plasmids . As shown in Figure 4c , the deletion of the carboxy-terminal sequence, downstream of aa 321, completely abolished the binding to the p73 protein by HCV core protein. This result indicates that the carboxy-terminal sequence, located between the aa 321 and 353, is necessary for p73/core interaction.
P73 overexpression causes nuclear translocation of coexpressed HCV core protein
To determine if p73/core interaction alters the subcellular localization of p73 or HCV core proteins, we performed indirect immunofluorescence experiments in HepG2 cells transfected with the pcDNA3-FLAGC2wt, pcDNA3-HA-p73 a (data not shown) and pcDNA3-HA-p73 b expression plasmids, either alone or in combination. As expected, full-length HCV core displayed a cytoplasmic distribution with evident perinuclear accumulation (Figure 5a ) , whereas p73 a or b were located in the nucleus (Figure 5d and data not shown). When p73 a or b were cotransfected with HCV core, the viral protein was translocated into the nucleus (Figure 5e and data not shown). These results indicate that p73/core interaction alters HCV core subcellular localization, thus favoring the ability of HCV core to modulate, directly or indirectly, cell transcription.
HCV core affects p73 a or b ability to control cell viability HCV core protein has been shown both to induce cellular proliferation (Moriya, 1997; Giambartolomei et al., 2001; Basu et al., 2002) and to modulate cell susceptibility to many proapoptotic stimuli (Zhu et al., 1998; Marusawa et al., 1999; Takamatsu et al., 2001) . In order to analyse whether p73/core interaction affects the control of cell viability by the p53 family members, we performed colony formation assay experiments. As shown in Figure 6a and b, p53, p73 a or b exert a strong negative effect on cell viability in both HepG2 and SAOS-2 cells, whereas overexpression of HCV core not only did not induce a loss of cell viability (Ray et al., 2000) , but its expression rather results in an increased number of colonies. HCV core coexpression almost completely inhibits the ability of p53 and p73 a to reduce cell viability in SAOS-2 (Figure 6a ) or HepG2 cells (Figure 6b ). When HCV core and p73 b were coexpressed, the capacity of HCV core protein to inhibit p73 b antiproliferative effect was restricted to the HepG2 cell line (Figure 6b) , and was not observed in SAOS-2 cells (Figure 6a ). Coexpression of p53 together with p73 b restores the ability of HCV core to counteract p73 b in SAOS-2 cells (Figure 6a black column). Similar results were obtained when we analysed the effects of HCV core protein on DNA synthesis by H 3 -methyl-thymidine incorporation (data not shown). Taken together our results indicate that core/p73 interaction prevents p73 a dependent cell growth arrest, independently from p53 status, whereas its effect on p73 b restores a functional p53. Our finding also suggests that p73 b may represent a 'last' cellular defence against the induction of cellular proliferation and apoptosis inhibition by HCV core protein in cells that have lost p53 functionality.
Discussion
HCC is the fifth malignant tumor in the world. Although a large number of risk factors are known, the molecular mechanisms underlying hepatocarcinogenesis are, until now, far from clear. The HCV polyprotein is processed to give raise to 10 viral proteins, including the core protein, which is part of the viral capsid and possesses multiple activities. In HCV infection in vivo, both an overproduction of HCV core protein and the presence of nonenveloped HCV nucleocapsids into the bloodstream of the infected hosts have been demonstrated (Maillard et al., 2001) . The nucleocapsid protein also accumulates in the hepatocytes of infected chimpanzees during the acute phase of infection. This accumulation of HCV core particles may represent a viral strategy to modulate both the host immune response and cellular homeostasis by inducing or inhibiting cell proliferation and/or apoptosis, according to the different viral life cycle necessities. The HCV core protein has been demonstrated both to induce and to inhibit programmed cell death (Ray et al., 1998; Lu, et al., 1999; Otsuka et al., 2000) . In addition, it has been shown that the different subcellular localization of innate and mature forms of HCV core protein causes opposite effects on p21 WAF1/CIP1 expression . The ability to exert opposite activities on cell cycle regulators is already well known for other oncogenic genes, such as myc and ras. In fact, myc can both induce cell growth or sensitize cells to cell death (Thompson, 1998) , whereas ras transforms immortalized fibroblasts, but it can also activate p53 and its direct target, the cyclin-dependent kinase inhibitor p21 WAF1/CIP1 (Serrano et al., 1997) . Indeed, several viral proteins interact directly with components of the highly conserved pathways that regulate cell cycle and block apoptosis to prevent premature death of the hostinfected cells and to permit an increase of virus progeny or to facilitate a persistent infection. On the other hand, induction of apoptosis helps to spread virus progeny to neighboring cells and contributes to the cytotoxicity associated with virus infection. Chronic induction of proliferation (Giambartolomei et al., 2001 ) and inhibition of apoptosis (Ray et al., 2000; Basu et al., 2002) by the HCV core protein are thought to allow cells to accumulate genetic mutations and to be more susceptible to transformation, thus rendering HCV virus potentially co-oncogenic. In order to further characterize the potential of HCV core protein to affect cell growth and cell viability, we investigated its functional interactions with the p53-related p73 proteins.
HCV core protein acts both as a p53 repressor (Ray et al., 2000) and as a p53 coactivator (Otsuka et al., 2000) . The actual amounts of core protein in infected cells may be an important determinant of the differential effects of HCV core on p53 and p73 cell growth regulatory functions. In fact, we show that HCV core expression at low concentration induces the p21
and Mdm2 p53/p73 target promoters, whereas higher amounts of HCV core protein inhibit p21 WAF1/CIP1 and Mdm2 activity. Indeed, the capacity of low HCV core protein levels to activate p21 WAF1/CIP1 and Mdm2 would cause a negative regulation of cell cycle progression (Sherr and Roberts, 1999) , whereas its ability to inhibit p21 WAF1/CIP1 and Mdm2 in a different cellular context (i.e. high HCV core levels) would result in an increased cell proliferation. Thus, the ability of HCV core protein to both upregulate and downregulate p21 WAF1/CIP1 and Mdm2 allows HCV to modulate cell cycle according to its necessities. Interestingly, we also demonstrate that HCV core protein always inhibits the proapoptotic Bax promoter. The overall biological effect of HCV core protein expression, as suggested by the colony formation assay results, should be however to suppress the p53 and p73 negative effects on cell viability by acting on both the p21 WAF1/CIP1
CDKi and the proapoptotic Bax protein(s).
We also demonstrate that HCV core protein physically interacts with different p73 isoforms and that this interaction, mediated by a region in the C-terminus of p73, causes a nuclear translocation of the viral protein. p73 is not inactivated by all the viral oncoproteins that are known to affect p53 functions. In fact, SV40 T antigen (Reichelt et al., 1999) and Ad E1B 55 kDa (Wienzek et al., 2000) cannot inactivate p73, while HPV E6 (Park et al., 2002) clearly does not induce p73 degradation and a controversy exists whether HPV E6 of low-and high-risk strains inactivates the transcriptional potential of p73 (Prabhu et al., 1998; Park et al., 2002) . On the other hand, p73 activity is inhibited by Ad E4orf6 (Higashino et al., 1998) and by HTLV-1 tax protein (Kaida et al., 2000) . Our study adds HCV core protein to the list of viral proteins able to interact with and to modulate p73. The physical interaction between HCV core and p73 proteins also provides a mechanistic explanation for the observed ability of HCV core protein to interfere with the control of cell proliferation by regulating several p73 target genes involved in growth arrest and apoptosis. Interestingly, HCV core protein differently modulates p73 a and b. The observation that, in p53-null cells, HCV core is unable to inhibit p73 b antiproliferative effects suggests that p73 b may play an important role to protect hepatocytes from HCV-related hepatocarcinogenesis. Further studies, which will assess the expression profile and the function of all p53 family members in chronically HCVinfected human hepatocytes, are however needed to clarify the role of HCV core and the p53 family in hepatocyte transformation and HCC development.
